PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
Update Offers More Comprehensive Understanding of PaxMedica’s Focus, Process and Progress
Tarrytown, NY, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has launched a newly updated corporate website at www.paxmedica.com.
Howard Weisman, Chief Executive Officer of PaxMedica, commented, “Our new website underscores our ongoing commitment to develop therapeutic advancements to treat core symptoms of autism and other potentially related disorders with intractable neurologic symptoms. The refreshed site represents the first step in providing a more robust platform for sharing information with our stakeholders, including families and investors, who are interested in our research.”
The new website provides easy access to essential information and other features while offering a more comprehensive understanding of PaxMedica’s focus on developing treatments for disorders with intractable neurologic symptoms such as Autism Spectrum Disorder (“ASD”). Key featurs of the refreshed website include an updated design and a more engaging interface, as well as better segmentation of the key subjects and sections.